CAS: 124937-51-5; (R)-2-(3-(Diisopropylamino)-1-Phenylpropyl)-4-Methylphenol

该化合物是一种主要用作治疗过活性膀胱的抗肌肉剂的药用化合物,它通过选择性地阻塞肌肉受体,帮助减少非自愿膀胱收缩和尿急症.托尔泰罗丁的化学配方是C19H25N,其分子重量约为281.42克/摩尔.这种物质通常以酸盐的形式施用,这提高了其溶性性和生物利用率.托尔泰罗丁的特点是其中性亲脂性,允许其有效跨过生物膜.它表现出相对较长的半衰期,它支持临床环境中每天一次的服用.普通副作用可能包括干嘴,静脉和眩晕,反映其抗胆碱性特性.由于其行动机制,在具有某些条件的病人中,例如窄角的 glaucoma 或 泌尿性保留量中,异体是反感体的.总的来说,托罗迪因在管理尿综合症方面有显著的进步,为病人提供抗体性症状.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号828933-86-4 (R)-6-methyl-4-... | CAS号108-18-9 二异丙胺 | CAS号848768-06-9 托特罗定 | CAS号40546-94-9 6-甲基-4-苯基色满-2-酮 | CAS号124935-88-2 2-甲氧基-5-甲基-N,N-... | CAS号106-44-5 对甲酚 | CAS号827007-19-2 (4R)-6-甲基-4-苯基色满-2-酮 | CAS号207679-81-0 (R)-5-羟甲基托特罗定 | CAS号286930-02-7 弗斯特罗定

合成工艺路线路线简述

    (R)-托特罗定l-酒石酸盐置于碳酸氢钠体系中,用 乙酸乙酯 用作溶剂,以6.9 G的收率获得托特罗定
    参考文献: Novel (R) And Rac 3-(2-(Allyloxy)-5-Methylphenyl)-N,N-Diisopropyl-3-Phenylpropan-1-Amine And Its Use For Synthesis Of (R) And Rac-2-(3-(Diisopropylamino)-1-Phenylpropyl)-4-(Hydroxymethyl)Phenol[fr] Nouveau (R) Et 3-(2-(Allyloxy)-5-Méthylphényl)-N,N-Diisopropyl-3-Phénylpropan-1-Amine Racémique Et Son Utilisation Pour La Synthèse De (R) Et De 2-(3-(Diisopropylamino)-1-Phénylpropyl)-4-(Hydroxyméthyl)Phénol Racémique
    标题: Novel (R) And Rac 3-(2-(Allyloxy)-5-Methylphenyl)-N,N-Diisopropyl-3-Phenylpropan-1-Amine And Its Use For Synthesis Of (R) And Rac-2-(3-(Diisopropylamino)-1-Phenylpropyl)-4-(Hydroxymethyl)Phenol[fr] Nouveau (R) Et 3-(2-(Allyloxy)-5-Méthylphényl)-N,N-Diisopropyl-3-Phénylpropan-1-Amine Racémique Et Son Utilisation Pour La Synthèse De (R) Et De 2-(3-(Diisopropylamino)-1-Phénylpropyl)-4-(Hydroxyméthyl)Phénol Racémique
    摘要:本发明涉及新颖的手性3-(2-(烯丙氧基)-5-甲基苯基)-N,N-二异丙基-3-苯丙胺(5)和消旋3-(2-(烯丙氧基)-5-甲基苯基)-N,N-二异丙基-3-苯丙胺()以及其在改进和工业上有利的制备手性和消旋形式2-(3-(二异丙胺基)-1-苯基丙基)-4-(羟甲基)苯酚的过程中的使用.此外,本发明还涉及其制备.

    海关参考信息

    专利信息


    专利号:WO-2017137955-A1
    优先权日:2016-02-14
    标题:Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
    发明人:THOMBARE PRAVIN SAHADEV
    权利人:CELESTIS PHARMACEUTICALS PVT LTD
    摘要:The present invention relates to novel chiral 3-(2-(allyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-amine (5) and racemic 3-(2-(allyloxy)-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-amine () and its use in improved and industrially advantageous process for preparation of chiral and racemic form of 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol. Further, present invention relates to preparation of the same.

    专利号:US-2008280855-A1
    优先权日:2005-06-22
    标 题 :Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles
    发明人:CHIESA MARIA VITTORIA; PALMER ANDREAS; BUHR WILM; ZIMMERMANN PETER JAN; BREHM CHRISTOF; SIMON WOLFGANG-ALEXANDER; POSTIUS STEFAN; KROMER WOLFGANG; ZANOTTI-GEROSA ANTONIO
    权利人:NYCOMED GMBH
    摘要:The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b. n n n n n n n n n n The compounds of the formula 1-a and the compounds of the formula 1-b, in which the substituents R1, R2, R3, and Ar have the meanings indicated in the description, are valuable intermediates for the preparation of pharmaceutically active compounds.

    专利号:EP-1862449-A1
    优先权日:2006-05-31
    标 题 :A shortened synthesis of substituted hydroxymethyl phenols
    发明人:BROWNE ROISIN; KIKELLY MICHAEL
    权利人:SCHWARZ PHARMA LTD
    摘要:The present disclosure relates to a process for the preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol or its phenolic monoesters or salts thereof, characterized by the steps of na) reacting a compound of formula (II)n nwith a mixture of MeMgCl and Mg in a solvent, nb) optionally reducing the temperature of the Grignard reagent to a lower temperature than in step a), and n nreacting the resulting Grignard reagent with an excess of a carbonate in a solvent, to obtain a compound of formula (III)n nwherein A is a C 1 -C 6 alkyl group, and then further reacting the compound of formula (III) in a known manner to obtain the desired end product.

    专利号:US-8299306-B2
    优先权日:2006-06-08
    标 题 :Accelerated synthesis of substituted hydroxymethyl phenols
    发明人:ENNIS SETH C; KENNEDY BRYAN D
    权利人:ENNIS SETH C; KENNEDY BRYAN D
    摘要:This disclosure relates to process for the preparation of a compound of formula (I) wherein R is hydrogen, a straight or branched C 1 -C 6 alkyl-carbonyl group or a phenylcarbonyl group, or a salt thereof, comprising the following steps: a) adding to a suspension of Mg a compound of formula (II) R 1 (MgX) n —LiY wherein n is 1 or 2; R 1 is an aromatic, aliphatic, carbocyclic or heterocyclic organic group having 1 to 24 carbon atoms; X and Y are independently selected from Cl, Br and I, b) reacting said reaction mixture with a suitable halogenated compound in a solvent to form a Grignard reagent, c) reacting said Grignard reagent with a suitable linear, branched or cyclic carbonate to obtain a compound of formula (IV) wherein A is a linear, branched or cyclic C 1 -C 6 alkyl group, and preferably a methyl group, and then further reacting the compound of formula (IV) in a known manner to obtain a compound of formula (I) and optionally salt formation.

    专利号:US-8703996-B2
    优先权日:2010-03-09
    标题:Short synthesis of tolterodin, intermediates and metabolites
    发明人:STERK DAMJAN
    权利人:STERK DAMJAN; LEK PHARMACEUTICALS
    摘要:A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.

    专利号:US-10035796-B2
    优先权日:2014-08-14
    标题:Crystalline forms of a BACE inhibitor, compositions, and their use
    发明人:KAZAKEVICH IRINA; TRZASKA SCOTT; FENG TAO
    权利人:MERCK SHARP & DOHME
    摘要:The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pathology and/or a symptom or symptoms thereof. Non-limiting examples of such Aβ pathologies, including Alzheimer's disease, are disclosed herein.
    福安药业(集团)股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.fapharm.com
    电话: 13962610789👤
    📞福安药业(集团)股份有限公司 ⚠️参考联系方式

    销售电话:13962610789
    邮箱:sales@fapharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015 Sep;16(9):60. doi: 10.1007/s11934-015-0531-9. Review. doi: 10.1186/1471-2490-14-84. Review.
    3: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review. Review. doi: 10.1517/14656566.2013.823158. Epub 2013 Jul 26. Review. doi: 10.2147/OAJU.S7232. Review.
    7: Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Review. Review. Epub 2009 May 14. Review.

    合成参考文献


    参考文献:10.1016/j.urology.2009.12.013
    摘要:Matsumoto Y, Miyazato M, Furuta A, Torimoto K, Hirao Y, Chancellor MB, Yoshimura N. Differential Roles of M2 and M3 Muscarinic Receptor Subtypes in Modulation of Bladder Afferent Activity in Rats. Urology. 2010 Apr;75(4):862–7. doi: 10.1016/j.urology.2009.12.013.
    参考文献:10.1155/2011/714978
    摘要:Masumori N, Miyamoto S, Tsukamoto T, Furuya S, Iwasawa A, Sato T, Itoh N, Shibuya A, Oda T. The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. Adv Urol. 2011;2011():714978.
    参考文献:10.2147/tcrm.s13883
    摘要:Masumori N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag. 2011;7():227–38.
    参考文献:10.1016/j.urology.2011.05.011
    摘要:Yoshida A, Seki M, Nasrin S, Otsuka A, Ozono S, Takeda M, Masuyama K, Araki I, Ehlert FJ, Yamada S. Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard. Urology. 2011 Sep;78(3):721.e7–721.e12. doi: 10.1016/j.urology.2011.05.011.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知